Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Cardiovascular, Renal and Metabolism, Medical Department, BioPharmaceuticals, AstraZeneca, Copenhagen, Denmark.
Nephrol Dial Transplant. 2024 Jun 28;39(7):1150-1158. doi: 10.1093/ndt/gfad271.
Chronic kidney disease (CKD) is a growing global health concern. Identifying individuals in routine clinical care with new-onset CKD at high risk of rapid progression of the disease is imperative to guide allocation of prophylactic interventions, but community-based data are limited. We aimed to examine the risk of rapid progression, kidney failure, hospitalization and death among adults with incident CKD stage G3 and to clarify the association between predefined risk markers and rapid CKD progression.
Using plasma creatinine measurements for the entire Danish population from both hospitals and primary care, we conducted a nationwide, population-based cohort study, including adults in Denmark with incident CKD stage G3 in 2017-2020. We estimated 3-year risks of rapid progression (defined by a confirmed decline in estimated glomerular filtration rate of ≥5 mL/min/1.73 m2/year), kidney failure, all-cause hospitalization and death. To examine risk markers, we constructed a heat map showing the risk of rapid progression based on predefined markers: albuminuria, sex, diabetes and hypertension/cardiovascular disease.
Among 133 443 individuals with incident CKD stage G3, the 3-year risk of rapid progression was 14.6% [95% confidence interval (CI) 14.4-14.8]. The 3-year risks of kidney failure, hospitalization and death were 0.3% (95% CI 0.3-0.4), 53.3% (95% CI 53.0-53.6) and 18.1% (95% CI 17.9-18.4), respectively. In the heat map, the 3-year risk of rapid progression ranged from 7% in females without albuminuria, hypertension/cardiovascular disease or diabetes, to 46%-47% in males and females with severe albuminuria, diabetes and hypertension/cardiovascular disease.
This population-based study shows that CKD stage G3 is associated with considerable morbidity in a community-based setting and underscores the need for optimized prophylactic interventions among such patients. Moreover, our data highlight the potential of using easily accessible markers in routine clinical care to identify individuals who are at high risk of rapid progression.
慢性肾脏病(CKD)是一个日益严重的全球健康问题。在常规临床护理中识别新发生 CKD 且疾病快速进展风险高的个体对于指导预防性干预措施的分配至关重要,但基于社区的数据有限。我们旨在检查新发生 CKD 3 期 G3 的成年人中快速进展、肾衰竭、住院和死亡的风险,并阐明预先定义的风险标志物与 CKD 快速进展之间的关系。
使用来自医院和初级保健的整个丹麦人群的血浆肌酐测量值,我们开展了一项全国性、基于人群的队列研究,包括 2017-2020 年丹麦新发生 CKD 3 期 G3 的成年人。我们估计了 3 年内快速进展(定义为经确认的估算肾小球滤过率下降≥5 mL/min/1.73 m2/年)、肾衰竭、全因住院和死亡的风险。为了检查风险标志物,我们构建了一个热图,根据预先定义的标志物显示快速进展的风险:蛋白尿、性别、糖尿病和高血压/心血管疾病。
在 133443 名新发生 CKD 3 期 G3 的个体中,快速进展的 3 年风险为 14.6%[95%置信区间(CI)14.4-14.8]。3 年内肾衰竭、住院和死亡的风险分别为 0.3%(95%CI 0.3-0.4)、53.3%(95%CI 53.0-53.6)和 18.1%(95%CI 17.9-18.4)。在热图中,快速进展的 3 年风险范围从无蛋白尿、高血压/心血管疾病或糖尿病的女性的 7%到严重蛋白尿、糖尿病和高血压/心血管疾病的男性和女性的 46%-47%。
这项基于人群的研究表明,CKD 3 期 G3 在社区环境中与相当大的发病率相关,并强调需要对这类患者进行优化的预防性干预。此外,我们的数据突出表明,在常规临床护理中使用易于获得的标志物来识别快速进展风险高的个体具有潜力。